A retrospective real world study assessing compared the effectiveness of Rd in combination with proteasome inhibitors, ixazomib (I), carfilzomib (K), and bortezomib (V), or monoclonal antibodies, elotuzumab (E) and daratumumab (D) with respect to treatment outcomes among RRMM patients in the United States (US) within subgroups defined by cytogenetic risk
Latest Information Update: 23 Jan 2023
At a glance
- Drugs Bortezomib (Primary) ; Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary) ; Proteasome inhibitors (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 23 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition